Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Blood advances·2026
Same author

Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.

Journal of Crohn's & colitis·2026
Same author

Training satisfaction, competency gaps and well-being in gastroenterology residency in Spain: results of a national SEPD survey.

BMC gastroenterology·2026
Same author

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

The Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn's Disease and Ulcerative Colitis)-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.

Therapeutic advances in gastroenterology·2026

Related Experiment Video

Updated: May 4, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

17.0K

Assessing an improved protocol for plasma microRNA extraction.

Inés Moret1, Dolors Sánchez-Izquierdo2, Marisa Iborra3

  • 1Instituto de Investigación Sanitaria del Hospital La Fe, Valencia, Spain ; CIBEREHD, CIBER de enfermedades hepáticas y digestivas, Barcelona, Spain.

Plos One
|December 31, 2013
PubMed
Summary

This study optimized microRNA extraction from human plasma, enhancing biomarker discovery. The best protocol uses column-based kits and specific RNA carrier doses for accurate results in clinical practice.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K

Related Experiment Videos

Last Updated: May 4, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

17.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Clinical Diagnostics

Background:

  • Peripheral blood (plasma, serum) is clinically relevant for biomarker discovery but presents challenges like complexity and low analyte concentrations.
  • Circulating microRNAs (miRNAs) are important small molecule biomarkers requiring robust extraction methods.
  • Existing RNA extraction protocols face limitations with blood-derived samples.

Purpose of the Study:

  • To establish an optimal RNA extraction method for microRNAs from human plasma.
  • To identify the best pre-analytical conditions and reagents for plasma miRNA isolation.
  • To improve the performance of assays for biomarker discovery in clinical settings.

Main Methods:

  • Analysis of various reagents and commercial kits for RNA extraction.
  • Evaluation of pre-analytical conditions for plasma sample isolation.
  • Comparison of column-based versus phenol-based extraction methods.
  • Assessment of RNA carrier impact on miRNA purification and potential bias.
  • Quality control using spectrophotometry and Agilent 2100 Bioanalyzer for RNA integrity.
  • Microarray analysis (Affymetrix) of differentially expressed miRNAs in plasma and biopsies.

Main Results:

  • Column-based RNA extraction methods, specifically the miRNeasy Serum/Plasma Kit, yielded more concentrated RNA suitable for microarrays.
  • Optimized low-dose RNA carrier addition improved miRNA purification without significant bias.
  • Established quality control metrics for protocol selection and RNA integrity.
  • Identified differentially expressed miRNAs between plasma and matched biopsies.

Conclusions:

  • An optimized protocol for microRNA purification from human plasma samples was defined.
  • The optimized method enhances assay performance for biomarker discovery.
  • This protocol provides a reliable approach for utilizing circulating miRNAs in clinical practice.